National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
Send to Printer
Endometrial Cancer Screening (PDQ®)     
Last Modified: 10/30/2008
Health Professional Version
Summary of Evidence

Benefits
Harms

Separate PDQ summaries on Endometrial Cancer Prevention 1; Endometrial Cancer Treatment 2; and Uterine Sarcoma Treatment 3 are also available.

Benefits

There is inadequate evidence that screening by ultrasonography (e.g., endovaginal ultrasound or transvaginal ultrasound [TVU]) or endometrial sampling (biopsy) would reduce the mortality from endometrial cancer. Most cases of endometrial cancer, however, are diagnosed because of symptoms, which are nonetheless “early” stage and have high survival rates.

Harms

Based on solid evidence, screening asymptomatic women with TVU will result in unnecessary additional examinations because of its low specificity. Based on solid evidence, endometrial biopsy may result in discomfort, bleeding, infection, and rarely uterine perforation. Risks associated with false-positive tests include anxiety and additional diagnostic testing.

  • Study Design: Evidence obtained from cohort studies.
  • Internal Validity: Fair.
  • Consistency: One study for endometrial biopsy and one study for hysteroscopy.
  • Magnitude of Effects on Health Outcomes: Small negative magnitude.
  • External Validity: Fair.


Table of Links

1http://www.cancer.gov/cancertopics/pdq/prevention/endometrial/HealthProfessional
2http://www.cancer.gov/cancertopics/pdq/treatment/endometrial/HealthProfessional
3http://www.cancer.gov/cancertopics/pdq/treatment/uterinesarcoma/HealthProfessio
nal